98%
921
2 minutes
20
Background: High levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) reflect poor cardiac status in heart failure patients.
Objectives: This study analyzed the association of preoperative NT-proBNP dynamics with 30-day and 5-year mortality after cardiac surgery.
Methods: A consecutive cohort of 6,938 patients undergoing cardiac surgery was analyzed. The relationship between preoperative NT-proBNP levels and 30-day and 5-year mortality (median follow up time: 4.53 [2.00-5.00] years) adjusted for EuroSCORE II was explored with a Cox proportional hazards model. The dynamics of preoperative NT-proBNP levels were analyzed by comparing the values at diagnosis or assignment to surgery with the values on the day before surgery (n = 4,739). Results were validated in an external cohort from the SWEDEHEART registry (n = 3,117).
Results: Median preoperative NT-proBNP concentration was 552 (208-1,591) ng/L. Death within 30 days occurred in 2.1% (149/6,938) of the population. High preoperative NT-proBNP levels were associated with higher 30-day and 5-year mortality. Initial high NT-proBNP at diagnosis, with subsequent decrease in preoperative NT-proBNP below 3,000 ng/L, was associated with more favorable perioperative outcomes after adjustment for EuroSCORE II shorter stays in intensive care unit (OR: 0.60, 95% CI: 0.44-0.82), less use of ultrafiltration (OR: 0.48, 95% CI: 0.33-0.70), or extracorporeal membrane oxygenation (OR: 0.26, 95% CI: 0.12-0.57; all P < 0.001) and lower 30-day mortality (HR: 0.21, 95% CI: 0.07-0.61; P = 0.004). Five-year survival was improved in patients with decreases in preoperative NT-proBNP levels (log-rank: P < 0.001, HR: 0.44, 95% CI: 0.30-0.65).
Conclusions: Reductions in NT-proBNP levels before surgery were associated with lower 30-day and 5-year mortality after cardiac surgery. Patients with high NT-proBNP concentrations may benefit from preoperative optimization to lower NT-proBNP.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409294 | PMC |
http://dx.doi.org/10.1016/j.jacadv.2025.102096 | DOI Listing |
JTCVS Open
August 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn.
Background: Proper risk stratification tools for patients with obstructive hypertrophic cardiomyopathy (oHCM) undergoing septal myectomy are lacking. Our objective was to assess the predictive value of preoperative N-terminal pro-brain natriuretic peptide (NT-proBNP) on perioperative outcomes and late survival in patients with oHCM undergoing transaortic septal myectomy.
Methods: Between 2008 and 2021, 834 patients with preoperative NT-proBNP measurements underwent septal myectomy.
JACC Adv
August 2025
Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. Electronic address:
Background: High levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) reflect poor cardiac status in heart failure patients.
Objectives: This study analyzed the association of preoperative NT-proBNP dynamics with 30-day and 5-year mortality after cardiac surgery.
Methods: A consecutive cohort of 6,938 patients undergoing cardiac surgery was analyzed.
Neurol Res
August 2025
Department of Neurology, the First Affiliated Hospital of Kunming Medical University, Kunming City, Yunnan Province, China.
Objective: To explore the features of serum amyloid A (SAA), the systemic immune inflammation index (SII), and N-terminal B-type natriuretic peptide (NT-proBNP) among individuals suffering from acute cerebral infarction (ACI), as well as their potential significance in assessing the adverse outcomes of thrombolytic treatment.
Methods: A total of 122 patients with ACI who underwent thrombolytic therapy were included in this single-center retrospective study. Patients were categorized into short-term good prognosis ( = 81) and short-term adverse outcomes ( = 41) groups on the basis of their prognosis within 6 months after the procedure.
Int J Cardiol Congenit Heart Dis
September 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Background: Valve regurgitation is associated with systemic ventricular dysfunction and mortality in patients with Fontan palliation. Valve repair and valve replacement with bioprostheses have limited durability, and outcomes after valve replacement with mechanical prostheses are poorly defined. The study objectives were to assess: (1) Operative mortality, valve-related complications (stroke, mechanical valve thrombosis, major bleeding complication, prosthetic valve endocarditis, and valve reoperation), and late mortality/transplant.
View Article and Find Full Text PDFSci Rep
August 2025
Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.
Troponin and N-terminal pro B-type natriuretic peptide (NT-proBNP) are biomarkers of cardiac damage and myocyte stretch. The existing evidence on the predictive value of preoperative high-sensitive Troponin and NT-proBNP concentration for the onset of postoperative atrial fibrillation (POAF) is inconsistent. Therefore, we aimed to assess these biomarkers as predictors for POAF in a prospective observational cohort study of patients without atrial fibrillation undergoing coronary artery bypass graft surgery (CABG).
View Article and Find Full Text PDF